Peptide profile · Healing & Recovery
Ziconotide (Prialt)
FDA-approved intrathecal analgesic derived from cone snail venom for severe chronic pain
Written & reviewed by Michael Carroll · Research, Peptide Initiative
Typical dose
Increase up to 2.4 mcg/day per step
Half-life
CSF: 4.6 hours; Plasma: 1.3 hours
Bioavailability
100% intrathecal; does not cross blood-brain barrier systemically
Molecular weight
2639.2 Da
Evidence level
Strong human trials
01 · Compound profile
Scientific & efficacy data
Molecular formula
C102H172N36O32S7
Primary benefits
FDA-approved N-type calcium channel blocker providing potent non-opioid analgesia for severe chronic pain refractory to other treatments
Unique mechanism of action independent of opioid receptors eliminates risks of tolerance, dependence, and respiratory depression
Specifically effective for neuropathic pain syndromes through selective blockade of pain signal transmission at the spinal cord
Elan Pharmaceuticals (now TerSera Therapeutics)
Amino acid sequence
25-amino acid peptide with 3 disulfide bridges (synthetic ω-conotoxin MVIIA)02 · Dosing
How much do I take?
Increase up to 2.4 mcg/day per step · no more than 2-3 times per week
Intrathecal: Infused into the fluid around the spinal cord, done in a hospital by a specialist.
Bioavailability Acts directly on the spinal cord/brain fluid — bypasses the bloodstream entirely.
Best time to take
Use Ziconotide (Prialt) at the same time each day for optimal results. Consistency in timing helps maintain stable levels and maximize therapeutic benefits. Follow your healthcare provider's specific instructions.
With food?
Ziconotide (Prialt) can generally be used with or without food. If you experience any discomfort, try taking it with a light meal. Follow specific guidance from your healthcare provider.
If stacking
Ziconotide (Prialt) should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
＋ Increase if
- +You've tolerated the current dose for the recommended period without significant side effects
- +Therapeutic goals haven't been met at the current dose level
- +Your healthcare provider recommends dose escalation based on your response
- +Lab work or clinical assessments support a higher dose
－ Decrease if
- −Side effects are bothersome or impacting daily life despite management strategies
- −You experience any signs of an adverse reaction
- −Lab results indicate the need for dose reduction
- −Your healthcare provider recommends a lower dose based on your response
✓ Signs of right dose
- ✓Therapeutic goals being met with minimal side effects
- ✓Stable and consistent response to treatment
- ✓Lab values or clinical markers trending in the right direction
- ✓Good tolerance with manageable or absent side effects
Dosing Calculator
Calculate Your Exact Dose
Step 1: Peptide Weight
Find the weight printed on your peptide vial label
Look here!
The peptide weight is printed on the label
Look here!
The weight is on the label
Select Weight
Look for a number followed by 'mg' on the vial label (e.g., 5mg, 10mg)
03 · Suitability
Is this right for me?
Best for severe chronic pain management & opioid-refractory neuropathic pain
Best for
Severe chronic pain management
Ziconotide (Prialt) is particularly well-suited for individuals focused on severe chronic pain management. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Opioid-refractory neuropathic pain
Ziconotide (Prialt) is particularly well-suited for individuals focused on opioid-refractory neuropathic pain. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Cancer-related intractable pain
Ziconotide (Prialt) is particularly well-suited for individuals focused on cancer-related intractable pain. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Reducing systemic opioid dependence
Ziconotide (Prialt) is particularly well-suited for individuals focused on reducing systemic opioid dependence. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Consider alternatives if
Do not use if
Use with caution if
Not sure?
Compare Ziconotide (Prialt) with similar peptides to find the best fit for your goals.
04 · Administration
How do I use it?
Intrathecal infusion
Reconstitution — what you need
Example
Add the recommended volume of bacteriostatic water to the Ziconotide (Prialt) vial. Gently swirl (do not shake) until the powder is fully dissolved. The resulting solution should be clear. Calculate your individual dose based on the concentration and your prescribed amount.
Your dose of Ziconotide (Prialt) is determined by your healthcare provider. Using an insulin syringe marked in units, draw up the exact amount prescribed. For example, if the reconstituted concentration is 1mg/mL and your dose is 0.5mg, draw up 0.5mL (50 units on an insulin syringe). Always double-check calculations before injection.
Route
Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Best sites
Technique
- 01Wash your hands thoroughly with soap and water before handling supplies
- 02Clean the injection site with an alcohol swab and let it air dry completely
- 03Pinch a fold of skin at the chosen injection site
- 04Insert the needle at a 45-90 degree angle (depending on needle length and body composition)
- 05Inject the medication slowly and steadily over 5-10 seconds
- 06Release the skin fold and remove the needle, applying gentle pressure with a clean swab
- 07Rotate injection sites to prevent tissue irritation or lipodystrophy
- 08Dispose of the needle safely in a sharps container—never recap or reuse needles
Storage · before reconstitution
Store Ziconotide (Prialt) in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
Storage · after reconstitution
Once reconstituted, Ziconotide (Prialt) should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Signs of degradation
Sample daily schedule
05 · Safety
Is it safe?
2 common side effects · 2 serious
Ziconotide (Prialt, FDA-approved since 2004) demonstrates favorable safety in intrathecal delivery with dose-dependent adverse effects primarily cognitive/psychiatric: dizziness, confusion, memory impairment, and mood changes in 20-50% of patients depending on infusion rate. Serious risks include meningitis-like aseptic meningitis (rare but documented), cognitive decline requiring dose reduction in ~25% of treated patients, and infection at intrathecal catheter insertion site. Hemodynamic effects (hypotension, dizziness) occur in dose-dependent fashion, necessitating slow titration (starting at 2.4 mcg/day, increasing weekly).
FDA approval based on Phase 2/3 trials in chronic pain patients demonstrating superior analgesia compared to placebo with manageable side effect profile when dosed carefully. Intrathecal route bypasses blood-brain barrier, achieving high spinal cord concentrations; safety monitoring must include cognitive/psychiatric assessment and CSF parameters. Over 15 years post-market experience supports acceptable benefit-risk profile in treatment-refractory cancer and non-cancer pain when dosed appropriately and infection risks minimized through proper catheter care.
Common side effects · experienced by some users
Less common
These typically resolve with continued use or dose adjustment.
Stop and seek help if
- ×Severe or worsening side effects that don't improve with dose adjustment or supportive care
- ×Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- ×Your healthcare provider recommends discontinuation based on your clinical response
- ×Development of any new medical condition that may be contraindicated with Ziconotide (Prialt)
- ×Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- ×Abnormal lab results or clinical markers that suggest adverse effects
Ziconotide (Prialt) should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
With other peptides
- ✓Baclofen — Intrathecal baclofen may complement ziconotide for mixed pain and spasticity syndromes
- ✓Gabapentin — Oral gabapentin addresses peripheral neuropathic pain through complementary calcium channel mechanisms
- ✓Physical Therapy — Rehabilitation combined with intrathecal analgesia optimizes functional recovery outcomes
With medications
- !CNS Depressants — May potentiate central nervous system depression including somnolence and confusion
- !Intrathecal Opioids — Concurrent intrathecal opioids increase risk of serious adverse events including respiratory depression
- !Psychotropic Medications — May exacerbate psychiatric adverse effects including hallucinations and psychosis risk
With supplements
- ✓Multivitamins — Generally safe to take alongside Ziconotide (Prialt). Space doses apart if taking oral formulations to ensure optimal absorption.
- ✓Electrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
06 · Effectiveness
How do I know it's working?
Strong human trials · first signs acute response (hours to days)
Evidence level
Strong human trials
(Phase 3 or FDA approved)
How it works
Ziconotide works like a natural pain-blocking substance that binds to calcium channels in your spinal cord. Calcium normally helps pain signals travel through your nerves, but ziconotide locks these channels and stops pain messages before they reach your brain. It's delivered directly into the fluid around your spinal cord through a special pump, which keeps pain relief extremely targeted without affecting your whole body.
Ziconotide is a 25-amino acid synthetic peptide derived from omega-conotoxin MVIIA, a toxin from the Conus magus cone snail. It acts as a selective antagonist of N-type voltage-gated calcium channels (Cav2.2) located on primary nociceptive nerve terminals in the superficial dorsal horn of the spinal cord. By blocking these channels, ziconotide prevents calcium influx necessary for synaptic vesicle fusion and neurotransmitter release from pain-signaling A-delta and C fibers. This blocks pain signal transmission at the spinal cord level without activating opioid receptors, making it suitable for opioid-refractory pain. The CSF half-life of approximately 4.6 hours enables continuous analgesia via intrathecal microinfusion pump delivery.
What to expect
Acute Response (Hours to Days)
What you might notice
- •Pain relief may begin within hours of intrathecal infusion initiation;
- •CSF half-life is 4.6 hours providing continuous analgesic coverage
What's normal
- •Initial response to Ziconotide (Prialt) is beginning at the cellular level
- •Different individuals experience Ziconotide (Prialt)'s onset at different rates
- •Transient systemic effects from initial Ziconotide (Prialt) exposure are common
What's next
- →Maintain consistent Ziconotide (Prialt) administration as prescribed
- →Document subjective effects and physical markers daily
- →Schedule a check-in with your provider about initial observations
Titration Period (1-3 Weeks)
What you might notice
- •Gradual dose optimization over 21 days with incremental increases;
- •progressive pain improvement as therapeutic dose is reached
What's normal
- •Ziconotide (Prialt) has achieved stable, long-term homeostatic integration
- •Sustained efficacy of Ziconotide (Prialt) remains consistent
- •Chronic Ziconotide (Prialt) effects remain stable and predictable
What's next
- →Maintain your established Ziconotide (Prialt) protocol for sustained benefits
- →Continue periodic monitoring to confirm Ziconotide (Prialt) efficacy
- →Review comprehensive Ziconotide (Prialt) response with your provider
Maintenance Therapy (Months to Years)
What you might notice
- •Sustained pain relief without tolerance development;
- •pump refills every 40-84 days;
- •long-term studies show continued efficacy beyond 1 year
What's normal
- •Full therapeutic effects of Ziconotide (Prialt) are well-characterized at this point
- •Maintenance of Ziconotide (Prialt)'s therapeutic effects is typical
- •Tolerance patterns with Ziconotide (Prialt) are generally stable over months
What's next
- →Comprehensive assessment of Ziconotide (Prialt) efficacy should be conducted
- →Discuss long-term continuation, cycling, or protocol modifications
- →Continue regular monitoring of relevant biomarkers or symptoms
Signs it's working · Treatment Response
- ✓Improvement in the primary symptoms or condition being treated
- ✓Positive changes in relevant lab values or clinical markers
- ✓Consistent, stable response to Ziconotide (Prialt) over time
- ✓Reduction in symptom frequency or severity
Signs it's working · General Well-being
- ✓Improved energy levels and daily functioning
- ✓Better quality of life related to the treated condition
- ✓Manageable or absent side effects indicating good tolerance
- ✓Positive feedback from healthcare provider during check-ups
Not seeing results? Common reasons
- •Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
- •Insufficient time at target dose—most compounds need several weeks to show full benefits
- •Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
- •Individual variation in response—genetics, metabolism, and other factors affect outcomes
- •Underlying conditions or medications interfering with absorption or effectiveness
- •Improper storage leading to degraded product—always verify proper storage conditions
Key research
07 · Questions
Frequently asked
How is ziconotide different from opioid pain medications?+
Ziconotide works through a completely different mechanism than opioids. It blocks N-type calcium channels at the spinal cord rather than activating opioid receptors. This means it does not cause respiratory depression, does not produce tolerance or physical dependence, and cannot be reversed by naloxone. It provides an alternative for patients who have failed opioid therapy.
Why does ziconotide require intrathecal administration?+
Ziconotide is a large peptide (25 amino acids) that cannot cross the blood-brain barrier when given systemically. Intrathecal delivery places the drug directly into the cerebrospinal fluid where it can access its target calcium channels on spinal cord neurons. This route also minimizes systemic side effects while maximizing spinal cord concentrations.
What is the FDA black box warning for ziconotide?+
Ziconotide carries a black box warning for neuropsychiatric adverse reactions. Patients may experience severe psychiatric symptoms including hallucinations, psychosis, paranoid reactions, and changes in mental status. It is contraindicated in patients with a pre-existing history of psychosis. Cognitive impairment and reduced consciousness may also occur.
Can ziconotide be used alongside other intrathecal medications?+
Ziconotide should be used cautiously with other intrathecal agents. While some practitioners combine it with intrathecal baclofen for mixed pain and spasticity, concurrent use with intrathecal opioids may increase the risk of serious adverse events. The drug should not be mixed with other medications in the same pump reservoir without compatibility data.
How long does it take for ziconotide to provide pain relief?+
Pain relief may begin within hours of starting the intrathecal infusion, as the drug's CSF half-life is approximately 4.6 hours. However, optimal pain relief typically requires a gradual titration period of 1-3 weeks, during which the dose is carefully increased based on individual response and tolerability.
What maintenance is required for the intrathecal pump?+
The programmable infusion pump requires periodic refills every 40-84 days depending on the drug concentration used and flow rate. Pump battery replacement surgery is needed approximately every 5-7 years. Regular follow-up visits are essential for dose adjustments, pump monitoring, and screening for catheter-related complications including infection.
08 · Further reading
History & related research
History · since 1970
Snake venom transformed into a powerful pain reliever that doesn't addict you.
Ziconotide is a pain medicine discovered from cone snail venom. A scientist named Baldomero Olivera collected snails in the Philippines and noticed their venom had interesting effects.
Read the full history of Ziconotide (Prialt)Studied for